Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosis Combines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative ...

FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN) Study will enroll and ...

Centogene NV and Twist Bioscience Corp. are linking up to develop custom assay kits for rare disease testing. The companies said the collaboration aims to make genetic tests more accessible to rare ...

In June 2020, CENTOGENE announced a partnership with Lufthansa and Fraport, the operator of Frankfurt airport, to open the first COVID-19 walk-in test center at Frankfurt Airport, providing on-site ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, ...

Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to ...

* CENTOGENE - WILL PROVIDE TESTING FOR MECKLENBURG-WESTERN POMERANIA REGION, EXPECTS TO EXPAND TESTING ACTIVITIES TO ADDITIONAL GEOGRAPHICAL AREAS Source text for Eikon: Billionaire fund manager Bill ...